Clinical Study
Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity
Table 1
Baseline demographic and clinical characteristics of patients with rheumatoid arthritis who received anti-TNF-alpha-adalimumab therapy.
| Characteristic | Number | % | Mean ± SD |
| Age (yrs) | | | 54.51 ± 13.16 | Body mass index (kg/m2) | | | 23.32 ± 3.50 | DAS28 score | | | 6.52 ± 0.72 | Sex | | | | Male | 15 | 21 | | Female | 56 | 79 | | Smoking | | | | No | 67 | 95 | | Yes | 4 | 5.2 | | Alcohol consumption | | | | No | 68 | 96 | | Yes | 3 | 4.2 | | Use of other RA mediations | | | | Methotrexate | | | | No | 0 | 0 | | Yes | 71 | 100 | | Hydroxychloroquine | | | | No | 0 | 0 | | Yes | 71 | 100 | | Leflunomide | | | | No | 57 | 80 | | Yes | 14 | 20 | | Cyclosporin | | | | No | 64 | 90 | | Yes | 7 | 9.9 | | Sulfasalazine | | | | No | 59 | 84 | | Yes | 12 | 17 | | Azathioprine | | | | No | 59 | 83 | | Yes | 12 | 17 | |
|
|
RA: rheumatoid arthritis; DAS28: disease activity score in 28 joints.
|